Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

Condition:   HIV-1 Intervention:   Drug: D/C/F/TAF FDC placebo Sponsor:   Janssen Pharmaceutica N.V., Belgium Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials